Report Description of the Rotavirus Vaccine Market

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for Substance Abuse Treatment Market


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Substance Abuse Treatment market


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy-based consulting analysis

EU Rotavirus Vaccine Market Executive Summary

The EU Rotavirus Vaccine Market is anticipated to observe a phase of consistent growth, owing to various factors affecting the healthcare sector such as focus of government expenditure towards healthcare sector primarily in research and development accompanied by structural changes introduced into the system to enable several healthcare providers to concentrate not only in ensuring sufficient volume is handled, but also ensuring quality of service is not compromised by healthcare providers.

Market Size and Key Findings

The EU Human Rotavirus Vaccine Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Rotavirus refers to a virus that mostly infects infants & childrens causing diarrhea. This is a contagious virus that shows its symptoms within two or three days of exposure to the virus. Initial symptoms of this infection are fever, vomiting, followed by diarrhea, and abdominal pain. The vaccines are used to help increase the immune system of the body and lowers the severity of an infection. The vaccination starts around six weeks of age and this should be done along with the promoting several activities such as handwashing, clean water, good sanitation, and breastfeeding.



Market Dynamics

Market Growth Drivers Analysis

Major factors for the Europe Human Rotavirus Vaccine market are increase in the awareness regarding vaccines among patients can accelerate the growth of this market. Rise in the population of immunity-compromised individuals can act as a catalyst for the market growth. Increase in the development and manufacturing of vaccine would enhance the market growth.

Market Restraints

Rotavirus therapeutics market is witnessing a substantial decrease in healthcare expenses in most of the advancing countries. This is one of the major reasons that is restraining thehuman rotavirus vaccine market from growing during the forecast period that will be ending in 2028. Thehuman rotavirus vaccine market is further, witnessing a rise in the prices of the vaccines and the adverse reactions alongside the increased side effects of the vaccine that are further estimated to bar the human rotavirus vaccine market shortly, as a part of the ongoing forecast period of 2021-2028.

Competitive Landscape

Key Players

Based on the Europe Human Rotavirus Vaccine market, the dominant players segmentation is further segmented is, Merck & Co., Inc., GlaxoSmithKline plc, Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd, BIOVIRx Inc. Biological E, and others

Products in Pipeline

Other candidate live oral vaccines are in development with the most advanced being RV3, a neonatal strain from Australia that is now in clinical trial. An important and perhaps distinguishing feature of this vaccine has been its good immunogenicity when administered in the newborn period allowing for a birth dose. While rotavirus is less common in the first 23 months of life, infants do get rotavirus in this period and a birth dose could further decrease their ultimate risk of disease in their first 5 years of life.

Notable Recent Deals

Biological E announced it had signed a licensing and co-operation agreement, in which Providence had agreed to sell up to 30 million doses of its PTX-COVID 19-B vaccine. Under the agreement, Providence will provide the necessary technology transfer for Biological E to make mRNA drugs in India with a maximum production capacity of 600 million units by 2022 and target a volume of one billion dollars. On July 8, 2021 GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that they have signed a Memorandum of Understanding with the European Commission to provide up to 220,000 doses of sotrovimab, a single dose of SARS-CoV-2 antibody for the treatment of adults and adolescents (elderly 12 years and older and weighing at least 40 kg). ) with COVID-19 which does not require the addition of oxygen and is at risk of further exposure to severe COVID-19. The Joint Procurement Agreement enables European Union (EU) Member States to participate in the immediate purchase of sotrovimab, following urgent local approval or EU-level approval, to treat patients at high risk with COVID-19 who may benefit from early treatment with sotrovimab.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

European Society for Paediatric Infectious Diseases and the European Society forPaediatricGastroenterology,HepatologyandNutritionrecommended thatrotavirusvaccination be offered to all healthy infants in Europe.Rotavirus vaccination and reimbursement policies from recommending bodies or national health agencies in each country in Europe.